Surgical therapy for colorectal metastases to the liver

Timothy M. Pawlik, Michael A. Choti

Research output: Contribution to journalArticle

Abstract

Colorectal cancer is the fourth most common type of cancer in the West and the second leading cause of cancer-related deaths in the United States. Approximately 35 to 55% of patients with colorectal cancer develop hepatic metastases during the course of their disease. Surgical resection of colorectal liver metastases represents the only chance at potential cure, and long-term survival can be achieved in 35 to 58% of patients after resection. The goal of hepatic resection should be to resect all metastases with negative histologic margins while preserving sufficient functional hepatic parenchyma. In patients with extensive metastatic disease who would otherwise be unresectable, ablative approaches can be used instead of or combined with hepatic resection. The use of portal vein embolization and preoperative chemotherapy may also expand the population of patients who are candidates for surgical treatment. Despite these advances, many patients still experience a recurrence after hepatic resection. More active systemic chemotherapy agents are now available and are being increasingly employed as adjuvant therapy either before or after surgery. Modern treatment of colorectal liver metastasis requires a multidisciplinary approach in an effort to increase the number of patients who may benefit from surgical treatment of colorectal cancer liver metastasis.

Original languageEnglish (US)
Pages (from-to)1057-1077
Number of pages21
JournalJournal of Gastrointestinal Surgery
Volume11
Issue number8
DOIs
StatePublished - Aug 2007

Fingerprint

Neoplasm Metastasis
Liver
Colorectal Neoplasms
Therapeutics
Drug Therapy
Liver Neoplasms
Portal Vein
Neoplasms
Recurrence
Survival
Population

Keywords

  • Chemotherapy
  • Colorectal metastasis
  • Liver
  • Radiofrequency ablation
  • Surgery

ASJC Scopus subject areas

  • Surgery

Cite this

Surgical therapy for colorectal metastases to the liver. / Pawlik, Timothy M.; Choti, Michael A.

In: Journal of Gastrointestinal Surgery, Vol. 11, No. 8, 08.2007, p. 1057-1077.

Research output: Contribution to journalArticle

Pawlik, Timothy M. ; Choti, Michael A. / Surgical therapy for colorectal metastases to the liver. In: Journal of Gastrointestinal Surgery. 2007 ; Vol. 11, No. 8. pp. 1057-1077.
@article{3dad563a1ba34aadab2180a34203a26b,
title = "Surgical therapy for colorectal metastases to the liver",
abstract = "Colorectal cancer is the fourth most common type of cancer in the West and the second leading cause of cancer-related deaths in the United States. Approximately 35 to 55{\%} of patients with colorectal cancer develop hepatic metastases during the course of their disease. Surgical resection of colorectal liver metastases represents the only chance at potential cure, and long-term survival can be achieved in 35 to 58{\%} of patients after resection. The goal of hepatic resection should be to resect all metastases with negative histologic margins while preserving sufficient functional hepatic parenchyma. In patients with extensive metastatic disease who would otherwise be unresectable, ablative approaches can be used instead of or combined with hepatic resection. The use of portal vein embolization and preoperative chemotherapy may also expand the population of patients who are candidates for surgical treatment. Despite these advances, many patients still experience a recurrence after hepatic resection. More active systemic chemotherapy agents are now available and are being increasingly employed as adjuvant therapy either before or after surgery. Modern treatment of colorectal liver metastasis requires a multidisciplinary approach in an effort to increase the number of patients who may benefit from surgical treatment of colorectal cancer liver metastasis.",
keywords = "Chemotherapy, Colorectal metastasis, Liver, Radiofrequency ablation, Surgery",
author = "Pawlik, {Timothy M.} and Choti, {Michael A.}",
year = "2007",
month = "8",
doi = "10.1007/s11605-006-0061-3",
language = "English (US)",
volume = "11",
pages = "1057--1077",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Surgical therapy for colorectal metastases to the liver

AU - Pawlik, Timothy M.

AU - Choti, Michael A.

PY - 2007/8

Y1 - 2007/8

N2 - Colorectal cancer is the fourth most common type of cancer in the West and the second leading cause of cancer-related deaths in the United States. Approximately 35 to 55% of patients with colorectal cancer develop hepatic metastases during the course of their disease. Surgical resection of colorectal liver metastases represents the only chance at potential cure, and long-term survival can be achieved in 35 to 58% of patients after resection. The goal of hepatic resection should be to resect all metastases with negative histologic margins while preserving sufficient functional hepatic parenchyma. In patients with extensive metastatic disease who would otherwise be unresectable, ablative approaches can be used instead of or combined with hepatic resection. The use of portal vein embolization and preoperative chemotherapy may also expand the population of patients who are candidates for surgical treatment. Despite these advances, many patients still experience a recurrence after hepatic resection. More active systemic chemotherapy agents are now available and are being increasingly employed as adjuvant therapy either before or after surgery. Modern treatment of colorectal liver metastasis requires a multidisciplinary approach in an effort to increase the number of patients who may benefit from surgical treatment of colorectal cancer liver metastasis.

AB - Colorectal cancer is the fourth most common type of cancer in the West and the second leading cause of cancer-related deaths in the United States. Approximately 35 to 55% of patients with colorectal cancer develop hepatic metastases during the course of their disease. Surgical resection of colorectal liver metastases represents the only chance at potential cure, and long-term survival can be achieved in 35 to 58% of patients after resection. The goal of hepatic resection should be to resect all metastases with negative histologic margins while preserving sufficient functional hepatic parenchyma. In patients with extensive metastatic disease who would otherwise be unresectable, ablative approaches can be used instead of or combined with hepatic resection. The use of portal vein embolization and preoperative chemotherapy may also expand the population of patients who are candidates for surgical treatment. Despite these advances, many patients still experience a recurrence after hepatic resection. More active systemic chemotherapy agents are now available and are being increasingly employed as adjuvant therapy either before or after surgery. Modern treatment of colorectal liver metastasis requires a multidisciplinary approach in an effort to increase the number of patients who may benefit from surgical treatment of colorectal cancer liver metastasis.

KW - Chemotherapy

KW - Colorectal metastasis

KW - Liver

KW - Radiofrequency ablation

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=34547141891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547141891&partnerID=8YFLogxK

U2 - 10.1007/s11605-006-0061-3

DO - 10.1007/s11605-006-0061-3

M3 - Article

VL - 11

SP - 1057

EP - 1077

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 8

ER -